TABLE 2.
Protection induced by Ebola VRP vaccinationa
| VRP immunogen | Dose (no. of IU) | No. of survivors/total no. of mice tested
|
|
|---|---|---|---|
| BALB/c | C57BL/6 | ||
| GP | 2.0 × 106 | 9/10 | 10/10 |
| NP | 2.0 × 106 | 10/10 | 15/16 |
| VP24 | 2.0 × 106 | 15/15 | 0/40 |
| VP30 | 2.0 × 106 | 25/25 | 25/25 |
| VP35 | 2.0 × 106 | 38/40 | 40/40 |
| VP40 | 2.0 × 106 | 15/15 | 16/20 |
| Lassa N | 2.0 × 106 | 0/20 | 0/20 |
a
Protection induced by VRPs expressing Ebola virus GP, NP, and VP proteins. Mice were vaccinated three times with 2.0 × 106 IU of VRPs as determined by the flow cytometry analysis of titer and then challenged with 1,000 PFU of mouse-adapted Ebola virus 28 days after the last vaccination. Mice were observed for 28 days after challenge.